Literature DB >> 25173351

TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome.

Monique Stoffels1, Johanna Jongekrijg1, Thijs Remijn1, Nina Kok1, Jos W M van der Meer1, Anna Simon2.   

Abstract

OBJECTIVE: The autoinflammatory hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS) is characterized by recurrent episodes of fever and inflammation. As part of the mevalonate kinase deficiency spectrum, it is caused by MVK mutations, resulting in decreased mevalonate kinase activity in the isoprenoid pathway. Although IL-1β is considered a major cytokine in its pathogenesis, IL-1 blockade is not successful in a proportion of patients. We aimed to further characterize the pro-inflammatory cytokine profile of HIDS.
METHODS: Peripheral blood mononuclear cells from HIDS patients and healthy donors were incubated with several stimuli. Cytokine concentrations were detected by ELISA. To analyse mRNA and protein expression, we performed quantitative RT-PCR and western blot, respectively.
RESULTS: We observed significant differences in cytokine production when cells were incubated with ligands for Toll-like receptor 2 (TLR2), TLR4 and nucleotide-binding oligomerization domain-containing 2 (NOD2). The increased ratio between active and inactive caspase-1 protein in HIDS patients could explain why these cells are more easily triggered to secrete IL-1β. This is apparently not regulated at the transcriptional level, since expression levels of caspase-1 and IL-1β mRNA were similar in patients and controls. Both anakinra and tocilizumab treatment resulted in decreased inflammation, both ex vivo as well as in vivo.
CONCLUSION: The increased cytokine secretion in HIDS is specific for TLR2, TLR4 and NOD2 ligation. Although IL-1β is important in the HIDS pathology, our data suggest it is a multicytokine disease. A more rigorous clinical trial is required to determine whether IL-6 receptor blockade may be considered in patients not responding to anakinra treatment.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  anakinra; autoinflammatory syndrome; hyper-IgD syndrome; mevalonate kinase deficiency; periodic fever; tocilizumab

Mesh:

Substances:

Year:  2014        PMID: 25173351     DOI: 10.1093/rheumatology/keu341

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  17 in total

Review 1.  Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.

Authors:  Svetlana Kostjukovits; Liisa Kalliokoski; Kaisu Antila; Matti Korppi
Journal:  Eur J Pediatr       Date:  2015-02-27       Impact factor: 3.183

2.  IgD class switching is initiated by microbiota and limited to mucosa-associated lymphoid tissue in mice.

Authors:  Jin Huk Choi; Kuan-Wen Wang; Duanwu Zhang; Xiaowei Zhan; Tao Wang; Chun-Hui Bu; Cassie L Behrendt; Ming Zeng; Ying Wang; Takuma Misawa; Xiaohong Li; Miao Tang; Xiaoming Zhan; Lindsay Scott; Sara Hildebrand; Anne R Murray; Eva Marie Y Moresco; Lora V Hooper; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

3.  Anti-interleukin 6 receptor therapy for hyper-IgD syndrome.

Authors:  Anne Musters; Paul Peter Tak; Dominique L P Baeten; Sander W Tas
Journal:  BMJ Case Rep       Date:  2015-10-29

Review 4.  Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?

Authors:  C M Mulders-Manders; A Simon
Journal:  Semin Immunopathol       Date:  2015-05-20       Impact factor: 9.623

5.  Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency.

Authors:  Cécile-Audrey Durel; Achille Aouba; Boris Bienvenu; Samuel Deshayes; Brigitte Coppéré; Bruno Gombert; Cécile Acquaviva-Bourdain; Eric Hachulla; Frédéric Lecomte; Isabelle Touitou; Jacques Ninet; Jean-Baptiste Philit; Laurent Messer; Marc Brouillard; Marie-Hélène Girard-Madoux; Michel Moutschen; Nadia Raison-Peyron; Pascal Hutin; Pierre Duffau; Pierre Trolliet; Pierre-Yves Hatron; Philippe Heudier; Ramiro Cevallos; Thierry Lequerré; Valentine Brousse; Vincent Lesire; Sylvain Audia; Delphine Maucort-Boulch; Laurence Cuisset; Arnaud Hot
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

6.  Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.

Authors:  Kimberly To; Ruoqiong Cao; Aram Yegiazaryan; James Owens; Timothy Nguyen; Kayvan Sasaninia; Charles Vaughn; Mohkam Singh; Edward Truong; Albert Medina; Edith Avitia; Jose Villegas; Christal Pham; Airani Sathananthan; Vishwanath Venketaraman
Journal:  Front Cell Infect Microbiol       Date:  2021-06-03       Impact factor: 5.293

7.  30 years hids-Travels between bedside and bench.

Authors:  Jos W M van der Meer
Journal:  Temperature (Austin)       Date:  2015-02-03

Review 8.  Mevalonate kinase deficiency: current perspectives.

Authors:  Leslie A Favier; Grant S Schulert
Journal:  Appl Clin Genet       Date:  2016-07-20

9.  Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases.

Authors:  Julie Jurczyluk; Marcia A Munoz; Oliver P Skinner; Ryan C Chai; Naveid Ali; Umaimainthan Palendira; Julian Mw Quinn; Alexandra Preston; Stuart G Tangye; Andrew J Brown; Elizabeth Argent; John B Ziegler; Sam Mehr; Michael J Rogers
Journal:  Immunol Cell Biol       Date:  2016-07-05       Impact factor: 5.126

Review 10.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.